openPR Logo
Press release

MoBiTec GmbH Provides AquaMutant Random Mutagenesis Reagent Kit for Mutagenesis of DNA and Cells

11-06-2013 06:00 PM CET | Science & Education

Press release from: MoBiTec GmbH

MoBiTec GmbH Provides AquaMutant Random Mutagenesis Reagent

Random mutagenesis is a powerful tool for life science research. AquaMutant can chemically modify nucleobases in vitro and in vivo. By treating biological samples, such as DNA, bacteria, and eukaryotic cells researchers can create mutant libraries. Random mutagenesis is widely used for analyzing wild-type protein function and creating proteins with new or improved functions (e.g., directed protein evolution).

Similar to error-prone PCR-based random mutagenesis, AquaMutant may be used to introduce random mutations limited to defined DNA sequence (e.g., a gene of interest) by treating a corresponding PCR product or restriction fragment in vitro. The treated DNA fragment, with or without further PCR amplification, may subsequently be ligated into a plasmid vector for expression.

However, unlike error-prone PCR-based random mutagenesis, AquaMutant also may be used to introduce random mutations in live cells or model organisms. Such in vivo random mutagenesis has many advantages: it is simple to carry out; it does not require prior genetic knowledge to study a phenotype; it can mutate multiple related genes concurrently and overcome the limitation of in vitro random mutagenesis where the mutation or knockout of a single gene may be compensated by other genes; and it is particularly suited for direct evolution to create mutants with desired properties by multiple rounds of mutation-selection.

Mutant libraries created by applying AquaMutant are useful tools in life science research to investigate biological processes and disease mechanisms, screen for enzymes and antibodies with improved properties, and use directed evolution to generate mutants with desired functionalities and phenotypes.

MoBiTec GmbH (Goettingen, Germany) is a privately held company (founded in 1987) that offers research tools for molecular and cell biology. Products include two- & one-hybrid systems for in vivo detection of molecular interactions, genomic libraries, DNA vectors for cloning and expression, kits for expression and purification of recombinant proteins, cell transfection reagents and cell culture tools, immobilized and soluble enzymes, products for genomics and proteomics research, numerous antibodies and recombinant proteins, superior fluorescence reagents and kits, affinity chromatography products as well as general laboratory equipment. In parallel to its own product lines, MoBiTec distributes products from international companies in Germany. MoBiTec products are distributed worldwide, in Germany from their home office, in other countries by distributors.

MoBiTec GmbH
Arne Schulz
Lotzestr. 22a
37083 Göttingen, Germany

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release MoBiTec GmbH Provides AquaMutant Random Mutagenesis Reagent Kit for Mutagenesis of DNA and Cells here

News-ID: 274807 • Views:

More Releases from MoBiTec GmbH

FerroFarRed - An Ion Indicator for the Specific Detection of Fe2+
FerroFarRed - An Ion Indicator for the Specific Detection of Fe2+
Intracellular Fe2+ can react with hydrogen peroxide, thereby producing the hydroxyl radical, a reactive oxygen species (ROS). Excessive ROS causes oxidative stress, resulting in cancer and neurodegenerative diseases. FerroFarRed (also known as SiRhoNox-1 or ER-SiRhoNox) is a fluorescent probe,manufactured by Goryo Chemical, Japan, distributed in Europe by MoBiTec GmbH, Germany. FerroFarRed specifically detects labile iron (II) ions (Fe2+) and is known to react with Fe2+ only, separately from other metal
TransIT-VirusGEN® Transfection Reagent - Ideal for Recombinant Adeno-associated Virus Production
TransIT-VirusGEN® Transfection Reagent - Ideal for Recombinant Adeno-associated …
TransIT-VirusGEN® Transfection Reagent by Mirus, USA, is designed to enhance delivery of packaging and transfer vectors to adherent and suspension HEK 293 cell types to increase recombinant adeno-associated virus (AAV) and lentivirus production. Adeno-associated virus (AAV) is a nonenveloped, single stranded DNA virus from the Paroviridae family notable for its lack of pathogenicity, low immunogenicity and ability to infect both dividing and quiescent cells. Because AAV is replication-defective in the
Elabscience's Vast Portfolio of Products for Life Science Research Distributed by MoBiTec Germany
Elabscience's Vast Portfolio of Products for Life Science Research Distributed b …
MoBiTec's most recent select partner Elabscience specializes in immunodiagnostic technology for the life science community, offering a complete platform for R&D and manufacture. Elabscience major products cover Proteins, Antibodies, ELlSA Kits, CLIA Kits, Labeling Kits,Biochemical Kits, Cell Lines, and Other Reagents. Elabscience also offers custom services for customers, including Protein Expression and Purification Service, Custom Antibody Service, Custom ELISA Service, Cell Biology Service, Molecular Biology Service, and Whole Research Project Solutions. Every
MoBiTec to Exhibit at Potsdam Days on Bioanalysis 2018, Taking Place in Potsdam, Germany
MoBiTec to Exhibit at Potsdam Days on Bioanalysis 2018, Taking Place in Potsdam, …
The "Potsdam Days on Bioanalysis" provide an excellent platform for researchers, clinicians, and entrepreneurs to discuss diagnostics' hot topics, trends, and recent developments as well as new areas of application and future markets. Often, the implementation of goal-oriented and profitable cooperations is quite a challenge, in particular when it comes to innovative product developments in the fields of diagnostics and analytics. Typically, challenges lie within finding the right cooperation partners, identifying

All 5 Releases


More Releases for Mutant

BRAF Mutant Metastatic Melanoma Market Outlook 2024-2034: Targeted Therapies and …
In 2024, the global BRAF mutant metastatic melanoma market is estimated at USD 1.6 billion. By 2034, it is projected to reach USD 3.9 billion, growing at a CAGR of 9.2% (2025-2034). This strong expansion reflects increasing mutation testing rates, broader use of targeted inhibitors, and rising adoption of combination immunotherapies across key regions. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71180 Market Overview: Key Highlights Market Size (2024): USD 1.6
BRAF-mutant Non-Small Cell Lung Cancer Pipeline: 10+ Companies Advancing Targete …
The treatment landscape for BRAF-mutant Non-Small Cell Lung Cancer (BRAF+ NSCLC), a molecular subtype of NSCLC driven by mutations in the BRAF gene, most commonly the V600E mutation, is rapidly evolving. Traditionally associated with poor prognosis, BRAF+ NSCLC has witnessed significant clinical progress with the development of targeted therapies that inhibit aberrant MAPK pathway signaling. With growing recognition of the heterogeneity and aggressiveness of BRAF-driven tumors, biopharmaceutical companies are increasingly
Mutant: The Digital Growth Catalyst for Startups
Image: https://www.abnewswire.com/uploads/3308ea53e26d2b7751959432f48accec.jpg Are you a startup with a brilliant idea? Need a partner to transform your vision into a thriving business? Look no further than Mutant, the premier full-service digital agency. We deliver creative digital solutions that drive growth and help startups like yours navigate the complex digital landscape. Experience the power of our cutting-edge digital transformation services, empowering you to achieve sustainable development and ensuring your business stands out in
HER2-mutant Non-Small Cell Lung Cancer Clinical Trials, Pipeline Insights, Treat …
DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the
BRAF-mutant Non-Small Cell Lung Cancer Pipeline Insights, Clinical Trials, Treat …
DelveInsight's, "BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight 2024," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the BRAF-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline
HER2-mutant Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical T …
DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the